Haemonetics HAE Income Statement
| TTM Q4 '26 | TTM Q3 '26 | TTM Q2 '26 | TTM Q1 '26 | TTM Q4 '25 | ||
|---|---|---|---|---|---|---|
| $1.33B-2.0% | $1.32B-4.0% | $1.33B-2.5% | $1.35B+0.9% | $1.36B+4.0% | ||
| $546.44M-10.7% | $535.85M-16.5% | $554.27M-14.1% | $579.77M-8.7% | $611.87M-0.9% | ||
| $787.59M+5.2% | $782.42M+6.9% | $773.59M+8.0% | $766.28M+9.6% | $748.96M+8.3% | ||
| 59%+4.0pp | 59.4%+6.1pp | 58.3%+5.6pp | 56.9%+4.5pp | 55%+2.2pp | ||
| $59.77M-4.7% | $63.63M+5.6% | $65.27M+13.1% | $64.53M+14.8% | $62.72M+15.2% | ||
| $442.42M+1.3% | $436.62M+1.3% | $433.93M-0.5% | $439.26M-1.2% | $436.79M+1.6% | ||
| $630.85M+19.7% | $531.33M-3.6% | $530.86M-3.3% | $530.35M-3.3% | $527.14M+0.1% | ||
| —— | $251.09M+39.2% | $242.73M+45.0% | $235.93M+56.3% | $221.82M+34.5% | ||
| -$28.7M-195% | -$23.93M-52.6% | -$25.62M-201% | -$25.41M-536% | -$9.75M+25.1% | ||
| —— | $227.17M+37.9% | $217.11M+36.7% | $210.53M+43.2% | $212.07M+39.6% | ||
| —— | $51.73M+49.2% | $48.92M+39.6% | $47.19M+47.0% | $44.39M+29.4% | ||
| —— | $175.44M+34.9% | $168.19M+35.8% | $163.34M+42.2% | $167.68M+42.6% | ||
| —— | $3.63+42.9% | $3.42+41.9% | $3.27+46.6% | $3.31+44.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Haemonetics's profit margins?
- Gross margin is 59.0% and operating margin is 19.0%, with a 13.3% net margin.
- Where does Haemonetics's income statement data come from?
- Every line is extracted from Haemonetics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.